NO20063368L - Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier - Google Patents
Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveierInfo
- Publication number
- NO20063368L NO20063368L NO20063368A NO20063368A NO20063368L NO 20063368 L NO20063368 L NO 20063368L NO 20063368 A NO20063368 A NO 20063368A NO 20063368 A NO20063368 A NO 20063368A NO 20063368 L NO20063368 L NO 20063368L
- Authority
- NO
- Norway
- Prior art keywords
- urinary tract
- lower urinary
- tract disorders
- alpha
- treatment
- Prior art date
Links
- 208000026723 Urinary tract disease Diseases 0.000 title abstract 3
- 208000014001 urinary system disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04001175A EP1557166A1 (fr) | 2004-01-21 | 2004-01-21 | Derives d'alpha-aminoamides pour le traitement des désordres de l'appareil urinaire inférieur |
| PCT/EP2005/000514 WO2005070405A1 (fr) | 2004-01-21 | 2005-01-20 | Derives d'alpha-aminoamide qui conviennent pour le traitement des troubles des voies urinaires inferieures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063368L true NO20063368L (no) | 2006-10-12 |
Family
ID=34626470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063368A NO20063368L (no) | 2004-01-21 | 2006-07-20 | Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7718815B2 (fr) |
| EP (1) | EP1557166A1 (fr) |
| JP (1) | JP2007518763A (fr) |
| KR (1) | KR101310882B1 (fr) |
| CN (1) | CN100584323C (fr) |
| AU (1) | AU2005205903B2 (fr) |
| BR (1) | BRPI0506970B8 (fr) |
| CA (1) | CA2554047A1 (fr) |
| IL (1) | IL176968A (fr) |
| NO (1) | NO20063368L (fr) |
| NZ (1) | NZ548638A (fr) |
| PL (1) | PL380825A1 (fr) |
| RU (1) | RU2395504C2 (fr) |
| WO (1) | WO2005070405A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2363983A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| US20080096965A1 (en) * | 2004-09-10 | 2008-04-24 | Newron Pharmaceuticals S.P.A. | (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| WO2007002885A2 (fr) * | 2005-06-29 | 2007-01-04 | University Of Virginia Patent Foundation | Compositions et procedes pour utiliser un agent de blocage du canal sodique |
| EP1963280B1 (fr) * | 2005-12-22 | 2015-10-28 | Newron Pharmaceuticals S.p.A. | Dérivés 2-phényléthylamino comme modulateurs des canaux de calcium et/ou sodium |
| DK2474521T3 (en) | 2006-06-19 | 2016-10-31 | Newron Pharm Spa | High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus |
| WO2008046087A2 (fr) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Composés spiro et leurs utilisations en tant qu'agents thérapeutiques |
| AR063280A1 (es) | 2006-10-12 | 2009-01-21 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos |
| DK2155663T3 (en) | 2007-06-15 | 2018-01-22 | Newron Pharm Spa | SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND / OR CALCIUM CHANNEL MODULATORS |
| KR101593627B1 (ko) | 2007-12-11 | 2016-02-11 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 고순도의 ２［４（３ 또는 ２플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법 |
| CN105218565A (zh) | 2008-10-17 | 2016-01-06 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| WO2010045197A1 (fr) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Composés spiro-oxindole et leur utilisation comme agents thérapeutiques |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| CN102753556B (zh) | 2009-10-14 | 2015-05-13 | 泽农医药公司 | 螺-羟吲哚化合物的合成方法 |
| NZ601667A (en) | 2010-02-26 | 2014-10-31 | Xenon Pharmaceuticals Inc | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| NZ602648A (en) | 2010-04-27 | 2014-10-31 | Newron Pharm Spa | Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| AU717598B2 (en) * | 1995-03-10 | 2000-03-30 | G.D. Searle & Co. | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
| GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| ES2352739T3 (es) * | 1997-11-21 | 2011-02-22 | Purdue Neuroscience Company | 2-aminoacetamidas sustituidas y el uso de las mismas. |
| GB9727523D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| SI1423168T1 (sl) * | 2001-09-03 | 2006-06-30 | Newron Pharm Spa | Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba |
| US20040209960A1 (en) | 2003-01-30 | 2004-10-21 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using sodium channell modulators |
| ES2339021T3 (es) | 2003-08-25 | 2010-05-14 | Newron Pharmaceuticals S.P.A. | Derivados de alfa-aminoamida utiles como agentes antiinflamatorios. |
-
2004
- 2004-01-21 EP EP04001175A patent/EP1557166A1/fr not_active Withdrawn
-
2005
- 2005-01-20 WO PCT/EP2005/000514 patent/WO2005070405A1/fr not_active Ceased
- 2005-01-20 CN CN200580002785A patent/CN100584323C/zh not_active Expired - Lifetime
- 2005-01-20 NZ NZ548638A patent/NZ548638A/en not_active IP Right Cessation
- 2005-01-20 PL PL380825A patent/PL380825A1/pl not_active Application Discontinuation
- 2005-01-20 AU AU2005205903A patent/AU2005205903B2/en not_active Expired
- 2005-01-20 US US10/586,494 patent/US7718815B2/en not_active Expired - Lifetime
- 2005-01-20 KR KR1020067014655A patent/KR101310882B1/ko not_active Expired - Lifetime
- 2005-01-20 CA CA002554047A patent/CA2554047A1/fr not_active Abandoned
- 2005-01-20 JP JP2006550030A patent/JP2007518763A/ja active Pending
- 2005-01-20 BR BRPI0506970A patent/BRPI0506970B8/pt not_active IP Right Cessation
- 2005-01-20 RU RU2006126346/04A patent/RU2395504C2/ru active
-
2006
- 2006-07-20 IL IL176968A patent/IL176968A/en active IP Right Grant
- 2006-07-20 NO NO20063368A patent/NO20063368L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20080132567A1 (en) | 2008-06-05 |
| NZ548638A (en) | 2010-02-26 |
| JP2007518763A (ja) | 2007-07-12 |
| BRPI0506970A (pt) | 2007-07-03 |
| CA2554047A1 (fr) | 2005-08-04 |
| EP1557166A1 (fr) | 2005-07-27 |
| CN1956714A (zh) | 2007-05-02 |
| PL380825A1 (pl) | 2007-03-19 |
| AU2005205903A1 (en) | 2005-08-04 |
| KR20070007776A (ko) | 2007-01-16 |
| IL176968A0 (en) | 2006-12-10 |
| CN100584323C (zh) | 2010-01-27 |
| HK1103282A1 (zh) | 2007-12-14 |
| BRPI0506970B1 (pt) | 2019-08-13 |
| KR101310882B1 (ko) | 2013-09-25 |
| WO2005070405A1 (fr) | 2005-08-04 |
| IL176968A (en) | 2012-10-31 |
| AU2005205903B2 (en) | 2010-04-29 |
| RU2006126346A (ru) | 2008-01-27 |
| RU2395504C2 (ru) | 2010-07-27 |
| US7718815B2 (en) | 2010-05-18 |
| BRPI0506970B8 (pt) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20070049L (no) | Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| EP2286839A3 (fr) | Traitement de l'obésité et de maladies liés à l'obésité | |
| NO20081842L (no) | Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer | |
| MY148985A (en) | 2-aminopyridine analogs as glucokinase activators | |
| NO20092637L (no) | Fremgangsmater for behandling | |
| NO20072665L (no) | Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser | |
| MX2010005345A (es) | Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad. | |
| NO20064732L (no) | Alfa-aminoamidderivater nyttige i behandlingen av urolige bein-syndromet og additive lidelser | |
| BRPI0506970B8 (pt) | derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior | |
| WO2006074265A3 (fr) | Therapie combinee et compositions pharmaceutiques utilisees dans le traitement des troubles inflammatoires | |
| PL1919466T3 (pl) | Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu | |
| DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
| WO2006086693A3 (fr) | Dispositifs medicaux | |
| EA200901062A1 (ru) | Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств | |
| NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
| NO20073610L (no) | Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase | |
| MX2007010484A (es) | Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. | |
| EA200801940A1 (ru) | Применение стробилуринов для лечения нарушений метаболизма железа | |
| WO2007055743A3 (fr) | Procédés pour traiter l'obésité et des troubles associés | |
| WO2006135694A3 (fr) | Composes modulateurs d'uii et utilisation | |
| WO2008022807A3 (fr) | Traitement et prévention de la fibrose intestinale | |
| WO2006109170A3 (fr) | Polytherapie destinee au traitement de maladies cardiovasculaires et de pathologies associees | |
| WO2006042277A3 (fr) | Compositions a liberation prolongee d'inhibiteurs de pompes a protons | |
| WO2007128088A3 (fr) | Utilisation de composés cytoprotecteurs de n-aminoimidazole pour traiter des maladies induites par la mort cellulaire et/ou par gsk-3 | |
| WO2008057543A3 (fr) | Composés modulant u ii et leur utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |